Analyst Research

Report Title Price
Provider: S&P Capital IQ Factual Report
Provider: GlobalData
Provider: Plunkett Research, Ltd.
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ventripoint Diagnostics Ltd Receives US-FDA Acceptance of 510 (K) Submission For Pulmonary Arterial Hypertension

Friday, 1 Mar 2013 09:00am EST 

Ventripoint Diagnostics Ltd announced that the U.S. Food and Drug Administration (US-FDA) that an administrative acceptance review was conducted on the 510(k) submission for premarket notification for right heart analysis in Pulmonary Arterial Hypertension (PAH), and it was found to contain all of the necessary information needed to proceed with the substantive review. The VMS is for investigational use only in the United States and approved for clinical use in Canada and Europe. 

Company Quote

-0.0050 -8.33%
21 Aug 2014